Business Context and Reporting Period
Quoin Pharmaceuticals Ltd. filed this Form 8-K on June 22, 2023, to report a material modification to the rights of security holders. The Company is incorporated in Israel and its American Depositary Shares (ADSs) trade on The Nasdaq Stock Market LLC under the symbol QNRX.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate action regarding share structure.
Material Changes
- ADS Ratio Change: The Board of Directors approved changing the ADS ratio from one ADS representing 5,000 Ordinary Shares to one ADS representing 60,000 Ordinary Shares.
- Reverse Split Effect: This change results in a one-for-twelve reverse split of issued and outstanding ADSs.
- Ordinary Shares: The change has no effect on the underlying Ordinary Shares.
- Effective Date: The Ratio Change is effective on or about July 17, 2023.
- Purpose: The action was taken to comply with the minimum bid price requirement of The Nasdaq Stock Market.
Guidance, Outlook, and Risks
Management expects the market price per ADS to increase proportionally to the ratio change. However, the Company explicitly states it can give no assurance that this action will result in satisfying or maintaining the Nasdaq minimum bid price requirement. No other guidance, risks, or contingencies are detailed in this specific filing.
Investor Verification Checklist
- Verify the exact effective date of the ratio change (expected July 17, 2023).
- Confirm the current market price of ADSs relative to the Nasdaq minimum bid price requirement post-split.
- Check for subsequent filings regarding the Company's compliance status with Nasdaq listing standards.
- Review the impact of the reverse split on the number of ADSs held in brokerage accounts.